Sulforaphane (mainly Broccoli) / Akt Cancer Research Results

SFN, Sulforaphane (mainly Broccoli): Click to Expand ⟱
Features:
Sulforaphane is an isothiocyanate derived from glucoraphanin, a compound found predominantly in cruciferous vegetables such as broccoli, Brussels sprouts, and cabbage. It is well known for its potent antioxidant and detoxification properties and has gained significant attention for its potential chemopreventive and anticancer effects.

Summary
1.primarily attenuates both DNMTs and HDACs, individually suppressing DNA hypermethylation and histones deacetylation, ultimately upregulating NRF2 (best known for NRF2↑)
2.Antioxidant Activity:
• Nrf2 activation leads to the upregulation of a host of antioxidant and detoxification enzymes (e.g., glutathione S-transferase, NAD(P)H:quinone oxidoreductase 1, heme oxygenase-1), which in turn decrease oxidative stress and lower ROS levels.
3.Pro-oxidant Effects in Cancer Cells and Under High-Dose Conditions (>=10uM?)
• In certain cancer cell types or at higher concentrations, sulforaphane can paradoxically lead to an increase in ROS levels.
• The elevated ROS may overwhelm the cancer cells’ antioxidant defenses, leading to oxidative stress–mediated cell death (apoptosis).
• This context-dependent pro-oxidant effect has been explored for its potential in selectively targeting cancer cells while leaving normal cells less affected.

- Might not be a good candidate for pro-oxidant strategy depending on concentration >10uM?.
- Strong Activation of Nrf2 (best known for) at low to moderate concentrations, hence reduces oxidative stress in both cancer and normal cells.
- AMPK signaling activated by SFN, high concentrations of ROS are produced
- ROS generation also results in depletion of GSH levels
- HIF-1α and VEGF inhibitor
- Might be effective against cancer stem cells
- But I would not combine that with radiation, as Sulforaphane activates the anti-oxidant master regulator of cells.
- “I very much agree: Sulforaphane is a very good addition, even more when the choice is an anti-oxidant therapy”
- well known as HDAC inhibitor (typically 5-10um concentrations)
-A transient decrease in HDAC activity has also been observed in healthy humans 3 h after providing a daily 200 µM SFN dose, resulting in a plasma concentration of SFN metabolites of 0.1–0.2 µM.


Dose/Bioavailabilty information:
SFN at a daily dose of 2.2 µM/kg body weight, with a mean plasma level of 0.13 µM Sprout 127.6 grams = 205uM±19.9 content yields SFN 0.5 to 2uM in plasma.
However, it is important to consider that at lower doses, specifically 2.5 μM, SFN resulted in a slight increase in cell proliferation by 5.18–11.84% within a 6 to 48 h treatment window.
-A therapeutic dose starts at approx 60 grams of the sprouts.
-100 g of Broccoli sprouts contain about 15–20 mg of sulforaphane
–Organic Broccoli Sprout Powder (Health Ranger) – Avmacol® – NanoPSA (a blend of NanoStilbene™ and Broccoli Sprout Extract).
- -750 mg Sulforaphane Glucosinolate in Daily One Serving (2 capsules) (30mg Sulforaphane)

Total sulforaphane metabolite concentration in plasma was the highest (>2 μM) at 3 h in human subjects who consumed fresh broccoli sprouts (40g)
-human studies with broccoli sprouts or extracts report plasma sulforaphane levels in the low micromolar range (typically 1–2 µM) after ingesting realistic, food-based quantities of sprouts (often in the range of 30–50 g of sprouts or a concentrated extract).

BroccoSprouts are young broccoli sprouts that have garnered attention because they contain high amounts of glucoraphanin—a precursor molecule to sulforaphane. Studies have shown that broccoli sprouts can have sulforaphane precursor levels (i.e., glucoraphanin levels) that are 10 to 100 times higher than those found in mature broccoli heads. Glucoraphanin content in broccoli sprouts can range anywhere from about 30 to over 100 mg per 100 grams of fresh sprouts. Once activated (e.g., during consumption when myrosinase acts on glucoraphanin), these levels translate into a significant sulforaphane yield, meaning that even a small amount of broccoli sprouts can deliver a potent dose of this bioactive compound.

Importantly, glucoraphanin itself is not bioactive. Rather, enzymatic hydrolysis by myrosinase, present in the plant tissue or in the mammalian microbiome, is necessary to form the active component, SFN.
- GFN (glucoraphanin) is hydrolyzed in vivo to SFN via the myrosinase, which is present in gut bacteria as well as the plant itself (also in Radish)
- Do not cook the vegetables, or if you do add myrosinase back in by adding radish.
- mild heat of broccoli (60–70 °C) inactivated ESP and preserved myrosinase and increased SF yield 3–7-fold
- chewing of fresh broccoli sprouts increases the interaction of glucosinolates with myrosinase and consequently, increases the bioavailability of SFN in the body

-Note half-life 2-3 hrs.
BioAv is good (15-80%) but requires myrosinase
Pathways:
- induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Lowers AntiOxidant defense in Cancer Cells: NRF2↓(contrary, actually most raises NRF2), TrxR↓**, GSH↓, Catalase↓(contrary), HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, Hh↓, GLi↓, GLi1↓, CD133↓, β-catenin↓, sox2↓, notch2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, 5↓, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 NRF2 / KEAP1 antioxidant response ↑ NRF2 (often insufficient for rescue) ↑ NRF2 (protective) Driver Electrophile-driven stress response Sulforaphane covalently modifies KEAP1, activating NRF2 signaling
2 Histone deacetylases (HDACs) ↓ HDAC activity ↔ mild modulation Driver Epigenetic reprogramming HDAC inhibition alters transcription of cell-cycle and apoptosis genes
3 Reactive oxygen species (ROS) ↑ ROS (transient / stress-inducing) ↓ ROS Secondary Redox signaling perturbation ROS rise reflects electrophilic stress rather than classic redox cycling
4 Cell cycle regulation ↑ G2/M or G1 arrest ↔ largely spared Secondary Cytostatic growth control Cell-cycle arrest is a prominent phenotype in cancer cells
5 Intrinsic apoptosis ↑ apoptosis (context-dependent) ↔ protected Phenotypic Threshold-dependent cell death Apoptosis occurs when stress exceeds adaptive capacity
6 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Secondary Suppression of inflammatory survival programs NF-κB inhibition supports anti-proliferative and anti-inflammatory effects


Akt, PKB-Protein kinase B: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport.

Inhibitors:
-Curcumin: downregulate AKT phosphorylation and signaling.
-Resveratrol
-Quercetin: inhibit the PI3K/AKT pathway.
-Epigallocatechin Gallate (EGCG)
-Luteolin and Apigenin: inhibit AKT phosphorylation


Scientific Papers found: Click to Expand⟱
7655- IP,  SFN,    Combined Phytochemical Sulforaphane and Dietary Fiber Inulin Contribute to the Prevention of ER-Negative Breast Cancer via PI3K/AKT/MTOR Pathway and Modulating Gut Microbial Composition
- in-vivo, BC, NA
Dose↝, Transgenic mice representing estrogen receptor-negative BC were fed 26% (w/w) BSp and 2% (w/v) inulin supplemented in food and water, respectively. The amount of BSp consumed by a mouse is equivalent to a daily intake of 234 g of BSp for an adult
TumCG↓, combinatorial treatment inhibited tumor growth, increased tumor onset latency, and synergistically reduced tumor weight.
TumW↓,
GutMicro↑, Ruminococcus, Muribaculaceae, and Faecalibaculum significantly increased, while Blautia, Turicibacter, and Clostridium sensu stricto 1 significantly decreased in the combinatorial group compared with the control group
HDAC↓, combinatorial treatment induced a protective epigenetic effect by inhibiting histone deacetylases (HDACs) and DNA methyltransferases (DNMTs).
DNMTs↓,
Akt↓, Intermediates in the AKT/PI3K/MTOR pathway were significantly suppressed by the combinatorial treatment, including PI3K p85, p-AKT, p-PI3K p55, MTOR, and NF-κB.
PI3K↓,
mTOR↓,
NF-kB↓,
TumCCA↑, Cell cycle arrest and programmed cell death were induced by the combinatorial treatment via elevating the expression of cleaved-caspase 3 and 7 and inhibiting the expressions of CDK2 and CDK4, respectively
cl‑Casp3↑,
cl‑Casp7↑,
CDK2↓,
CDK4↓,
Risk↓, Overall, the findings suggest that early-life dietary combinatorial treatment contributed to BC prevention
Dose↝, The dosage of inulin used in this experiment was lower than that used in a previous study, which suggested that 8% (w/v) inulin, equivalent to 40 g of fiber per day, is physiologically achievable and practical for human patients

9194- ITCs,  SFN,  BITC,    Erucin and benzyl isothiocyanate suppress growth of late stage primary human ovarian carcinoma cells and telomerase activity in vitro
- in-vitro, Ovarian, NA
tumCV↓, Twenty-four hour exposure of carcinoma cells to 5-50 μM erucin or benzyl ITC led to a concentration-dependent viability loss,
DNAdam↑, This concurred with an increase in internucleosomal DNA fragmentation, mitochondrial membrane depolarization and downregulation of Akt as indicator for apoptosis induction.
MMP↓,
Akt↓,
TumCCA↑, Cell accumulation at the G2/M phase was evident after 48 h of erucin treatment.
Telomerase↓, Telomerase, a selective target of cancer cells, was suppressed by erucin.

9191- ITCs,  AITC,  BITC,  PEITC,  SFN  Molecular Targets of Isothiocyanates in Cancer: Recent Advances
- Review, Var, NA
Risk↓, Various recent epidemiological studies have indicated that consumption of cruciferous vegetables such as garden cress, broccoli, etc., reduces the risk of cancer.
TumCG↓, ITCs suppress tumor growth by generating reactive oxygen species or by inducing cycle arrest leading to apoptosis.
ROS↑,
TumCCA↑,
Apoptosis↑,
Ingr?, Some of the widely studied ITCs that have potent anti-cancer effects are Allyl isothiocyanate (AITC), Benzylisothiocyanate (BITC), Phenethylisothiocyanate (PEITC) and Sulforaphane (SFN).
chemoPv↑, Chemopreventive effects of ITCs are exerted by inhibition of the bio-activation of carcinogens. PEITC has been shown to possess significant chemopreventive properties against tobacco-induced carcinogens in rodent models of lung and esophageal cancer
P450↓, BITC suppresses cytochrome P450 2E1 while sulforaphane inhibits cytochrome P450 1A2 [
SXR↓, Sulforaphane also has been shown to inhibit steroid and xenobiotic receptor (SXR), a nuclear hormone receptor that regulates expression of CYP3A4
CYP3A4↓,
NRF2↑, ITCs induce the Nrf2 transcription factor to activate ARE
ARE↑,
HO-1↑, SFN mediated induction of Nrf2 was found to be through the activation of heme oxygenase 1 and inhibition of p38 in hepatoma cells
p38↓,
TrxR↑, several studies have shown induction of thioredoxin reductase as well its substrate thioredoxin by SFN in various cancer cell lines
Trx↑,
NF-kB↓, Inhibition of key survival pathway such as NF-kB and AP-1 by ITCs also contributes to the chemopreventive effects of ITCs [
AP-1↓,
BioAv↑, intracellular concentrations of ITCs can reach up to 100–200 folds higher than the extracellular concentrations. For example when hepatoma cells were incubated with 100μM SFN for about 30 mins, the intracellular concentrations reached about 6.4mM
Akt↓, via inhibition of key molecules overexpressed in cancer such as AKT, STAT3, HDAC and NF-kB
STAT3↓,
HDAC↓,
VEGF↓, BITC Anti-angiogenesis Pancreas ↓VEGF, MMP-2, HIF-a In vitro 5, 10,20 μM/24 h BxPC-3,PanC-1 [77] ↑RhoB ↓STAT-3 phosphorylation (Tyr-705), HIF-a, VEGFR-2, VEGF, MMP-2, CD31, RhoC.
MMP2↓,
Hif1a↓,
CD31/PECAM-1↓,
PI3K↓, BITC Apoptosis Pancreas ↓PI3K, AKT, PDK1, mTOR, FOXO1, FOXO3a In vitro 5, 10, 20 μM/24h BxPC-3,PanC-1 [55] ↑Bim, p27, and p21
PDK1 / PDPK1↓,
mTOR↓,
FOXO1↓,
FOXO3↓,
BIM↑,
p27/CDKN1B↑,
P21↑,
HER2/EBBR2↓, PEITC Apoptosis Breast ↓HER2, EGFR, STAT-3, BCL-XL, XIAP, ROS In vitro 10 μM/24 h MDA-MB-231, MCF-7 [95] ↑Bax, Bim, HER2
EGFR↓,
Bcl-xL↓,
XIAP↓,
ROS↓,
Zeb1↓, SFN Anti-metastasis Bladder ↓ZEB1, Snail In vitro 0–20μM/24h T24 [154] ↑E-cadherin
Snail↓,
E-cadherin↑,
MMP2↓, AITC Anti-metastasis Liver ↓MMP-2/-9 In vitro 0.1–5 μM/24 h SK-Hep 1
MMP9↓,
ROS↑, ROS generation leads to disruption of mitochondrial membrane potential and release of pro-apoptotic molecules resulting in activation of caspase-mediated cell death [63, 81, 83].
MMP↓,
Casp↑,
DNAdam↑, ROS induced by BITC also DNA damage and G2/M cell cycle arrest as detected through increased phosphorylation of H2A.X
TumCCA↑,
γH2AX↑,
CSCs↓, dietary BITC also suppressed the growth of cancer stem cell in MMTV-neu breast cancer transgenic mice model along with inhibition of major stem cell markers like Oct4, SOX-2 and Nanog
OCT4↓,
SOX2↓,
Nanog↓,
NOTCH2↑, In contrast, the activation of NOTCH2 signaling by BITC was found to impede the therapeutic benefits of BITC
selectivity↝, Like BITC, PEITC also induces ROS generation selectively in cancer cells
ETC↓, PEITC disrupts mitochondrial electron transport chain (ETC) by inhibiting Complex I and III activity and reduces oxygen consumption rate in prostate cancer cells
compI↓,
compIII↓,
OCR↓,
Synergy↑, ITCs exhibit a diverse range of cellular targets for anti-cancer effect. This property of ITCs makes them highly desirable for combinatorial therapeutic approaches.
ChemoSen↑, BITC:20μM (1h) Cisplatin 15, 30, 45μM (48h) Lung ↓ β-Tubulin Sensitization
RadioS↑, combination of BITC or SFN with the radiation therapy caused increased G2/M cell cycle arrest
Synergy↑, PEITC:0.025% in diet (10 and 16 weeks) Curcumin 1% in diet (10 and 16 weeks) Prostate ↓ PDK-1/AKT Synergistic
Synergy↑, SFN:25μM (24h) Resveratrol 25μM (24h) Glioma cells ↓ LDH, ↓ AKT, ↑ Caspase 3 cleavage Synergistic
Synergy↑, SFN:Quercetin Pancreatic cancer stem cells ↓ BCL-2, ↓ XIAP, ↑ Caspase 3 cleavage Synergistic
Synergy↑, SFN:10μM (6days) Epigallocatechin gallate 20μM (6days) Ovarian ↓ hTERT, ↓ BCL-2 Synergistic
Synergy↑, DIM synergizes with SFN leading to enhanced cell cycle arrest in colon cancer cells

9173- ITCs,  SFN,    Dietary isothiocyanates and anticancer agents: exploring synergism for improved cancer management
- Review, Var, NA
Synergy↑, Our analysis reveals the potential of these synergies to augment therapeutic efficacy, mitigate chemoresistance, and minimize toxic effects, thereby opening avenues for therapeutic innovation.
AntiCan↑, Isothiocyanates, such as sulforaphane (SFN), allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), and phenethyl isothiocyanate (PEITC), are metabolized from glucosinolates and renowned for their potent anticancer properties.
chemoP↑, Beyond prevention, ITCs show promise in synergizing with conventional anticancer agents, potentially amplifying therapeutic efficacy while minimizing the adverse side effects typically associated with chemotherapy.
ChemoSen?, ITCs, notably SFN, have been shown to induce chemosensitization in cancer cells.
toxicity↓, At low doses, ITCs can promote the growth of both normal and cancer cells, whereas high doses are toxic to cancer cells.
ROS↑, At low concentrations, ITCs may activate mild oxidative stress, leading to the adaptive activation of protective pathways like Nrf2, enhancing cellular defenses against carcinogens. However, at therapeutic concentrations, ITCs exert pronounced cytoto
NRF2↑,
NF-kB↓, inhibition of the nuclear factor kappa B (NF-κB),
CYP1A1↓, Specifically, ITCs inhibit phase I enzymes, such as Cytochrome P450 enzymes (CYP1A1, CYP1A2, and CYP1B1), responsible for pro-carcinogens bioactivation.
CYP1A2↓,
CYP1B1↓,
TumCCA↑, By inducing cell cycle arrest, ITCs prevent cancer cells from entering mitosis, thereby impeding tumor growth and progression
PI3K↓, SFN has been identified to downregulate the PI3K/AKT/mTOR signaling pathway and upregulate the expression of PTEN, a tumor suppressor gene.
Akt↓,
mTOR↓,
PTEN↑,
BAX↑, SFN enhances the production of Bax, a pro-apoptotic protein, thereby promoting apoptosis in cancer cells.
ChemoSen↑, SFN can enhance the efficacy of chemotherapeutic agents such as cisplatin and doxorubicin (DOX)
Synergy↑, Furthermore, a tri-combination involving SFN, GEN, and sodium butyrate (NaB) resulted in even more pronounced synergistic inhibition in breast cancer, reaching a minimum CI value of 0.06 in MCF-7 cells
Synergy↑, The first study by Langner et al. (74) investigated a blend (referred to as MIX) of lycopene, SFN, quercetin, and curcumin. It revealed an additive effect in the reduction of colon cancer cell proliferation.
Synergy↑, The second study investigated the synergistic effects of SFN with curcumin and dihydrocaffeic acid (DA) against colon cancer cells
Synergy↑, Combining BITC and SFN proved more effective than either compound alone in reducing cell viability. This combination exhibited an enhanced reduction in pSTAT3 levels and an amplified increase in apoptosis, evident through PARP cleavage.
Synergy↑, Furthermore, the combination of SFN with AITC has demonstrated synergistic effects in non-small cell lung carcinoma cells, manifested by increased production of intracellular ROS and concomitant suppression of cancer cell proliferation
Dose↝, In this review, we define low doses of SFN as 1–5 μM and high doses as above 10 μM, based on concentrations used in cited studies.
Synergy↑, Additionally, up to 1.5 μM SFN can enhance cisplatin sensitivity through the accumulation of intracellular cisplatin in ovarian cancer cells

5002- Sal,  SFN,    Salinomycin and Sulforaphane Exerted Synergistic Antiproliferative and Proapoptotic Effects on Colorectal Cancer Cells by Inhibiting the PI3K/Akt Signaling Pathway in vitro and in vivo
- in-vivo, CRC, Caco-2 - vitro+vivo, CRC, CX-1
Apoptosis↑, we evaluated the molecular mechanism behind SAL- and SFN-mediated CRC cell apoptosis.
PI3K↓, The combination treatment induced apoptosis in Caco-2 and CX-1 cells by inhibiting the PI3K/Akt pathway, which increased the expression of the tumor suppressor protein p53.
Akt↓,
P53↑,
BAX↑, The treatment also decreased the expression of the survival protein Bcl-2 and increased the expression of the proapoptotic protein Bax, which increased the Bax/Bcl-2 ratio
Bax:Bcl2↑,
p‑PARP↑, as well as enhanced poly ADP-ribose polymerase (PARP) cleavage.
TumCMig↓, Cotreatment also significantly decreased migration and invasion compared to that of the control and SAL or SFN monotherapies.

2445- SFN,    Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, SkBr3
TumCCA↑, SFN (5-10 µM) promoted cell cycle arrest, elevation in the levels of p21 and p27 and cellular senescence
P21↑,
p27/CDKN1B↑,
NO↑, effects were accompanied by nitro-oxidative stress, genotoxicity and diminished AKT signaling
Akt↓,
ATP↓, decreased pools of ATP and AMPK activation, and autophagy induction
AMPK↑,
TumAuto↑,
DNMT1↓, decreased levels of DNA methyltransferases (DNMT1, DNMT3B)
HK2↓, A decrease in HK2 levels was observed in SFN-treated MDA-MB-231 cells
PKM2↓, and a decrease in PKM2 levels was noticed in SFN-treated MDA-MB-231 and SK-BR-3 cells
HDAC3↓, . In contrast, HDAC3 , HDAC4 , HDAC6 , HDAC7 , HDAC8 ), HDAC9 and HDAC10 (histone deacetylase 10) mRNA levels were decreased in SFN-treated MDA-MB-231 cells
HDAC4↓,
HDAC8↓,

3195- SFN,    AKT1/HK2 Axis-mediated Glucose Metabolism: A Novel Therapeutic Target of Sulforaphane in Bladder Cancer
- in-vitro, Bladder, UMUC3
ATP↓, SFN strongly downregulates ATP production by inhibiting glycolysis and mitochondrial oxidative phosphorylation (OXPHOS).
Glycolysis↓,
OXPHOS↓,
HK2↓, SFN weaken the glycolytic flux by suppressing multiple metabolic enzymes, including hexokinase 2 (HK2) and pyruvate dehydrogenase (PDH).
PDH↓,
AKT1↓, SFN decreases the level of AKT1 and p-AKT ser473 , especially in low-invasive UMUC3 cells.
p‑Akt↓,

1458- SFN,    Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma
- Review, Bladder, NA
HDAC↓, SFN’s role as a natural HDAC-inhibitor is highly relevant
eff↓, SFN exerts stronger anti-proliferative effects on bladder cancer cell lines under hypoxia, compared to normoxic conditions
TumW↓, mice, SFN (52 mg/kg body weight) for 2 weeks reduced tumor weight by 42%
TumW↓, In another study a 63% inhibition was noted when tumor bearing mice were treated with SFN (12 mg/kg body weight) for 5 weeks
angioG↓,
*toxicity↓, In both investigations, the administration of SFN did not evoke apparent toxicity
GutMicro↝, SFN may protect against chemical-induced bladder cancer by normalizing the composition of gut microbiota and repairing pathophysiological destruction of the gut barrier,
AntiCan↑, A prospective study involving nearly 50,000 men indicated that high cruciferous vegetable consumption may reduce bladder cancer risk
ROS↑, Evidence shows that SFN upregulates the ROS level in T24 bladder cancer cells to induce apoptosis
MMP↓,
Cyt‑c↑,
Bax:Bcl2↑,
Casp3↑,
Casp9↑,
Casp8∅,
cl‑PARP↑,
TRAIL↑, ROS generation promotes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity
DR5↑,
eff↓, Blockade of ROS generation inhibited apoptotic activity and prevented Nrf2 activation in cells treated with SFN, pointing to a direct effect of ROS on apoptosis
NRF2↑, SFN potently inhibits carcinogenesis via activation of the Nrf2 pathway
ER Stress↑, endoplasmic reticulum stress evoked by SFN
COX2/PTGS2↓, downregulates COX-2 in T24 cells
EGFR↓, downregulation of both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2/neu
HER2/EBBR2↓,
ChemoSen↑, gemcitabine/cisplatin and SFN triggered pathway alterations in bladder cancer may open new therapeutic strategies, including a combined treatment regimen to cause additive effects.
NF-kB↓,
TumCCA?, cell cycle at the G2/M phase
p‑Akt↓,
p‑mTOR↓,
p70S6↓,
p19↑, p19 and p21, are elevated under SFN
P21↑,
CD44↓, CD44s expression correlates with induced intracellular levels of ROS in bladder cancer cells variants v3–v7 on bladder cancer cells following SFN exposure
CSCs↓, CD44 is not only involved in cytoskeletal changes and cellular motility but also serves as a cancer stem cell (CSC) marker

1459- SFN,  AF,    Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway
- in-vitro, Liver, Hep3B - in-vitro, Liver, HepG2
eff↑, sulforaphane significantly enhanced auranofin-induced apoptosis by inhibiting TrxR activity and cell proliferation compared to either single treatment
TumCCA↑, Sub-G1 cells
Apoptosis↑,
MMP↓,
BAX↑,
cl‑PARP↑,
Casp3↑,
Casp8↑,
Casp9↑,
ROS↑, combined treatment induced excessive generation of reactive oxygen species (ROS)
eff↓, treatment with N-acetyl-L-cysteine, a ROS scavenger, reduced combined treatment-induced ROS production and apoptosis.
PI3K↓,
Akt↓,
TrxR↓, treatment with either sulforaphane or auranofin alone at low concentrations weakly inhibit TrxR activity Combined treatment significantly reduced TrxR activity and cell viability
BAX↑,
Bcl-2∅,

1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓,
TumCCA↑, G2/M phase
Apoptosis↑,
TumCMig↓,
TumCI↓,
EMT↓,
Slug↓,
Twist↓,
MMP2↓,
MMP9↓,
TumCG↓,
p‑Akt↓,
P21↑,
ERK↑,
p38↑,
ROS↑, ROS was significantly induced in both FTC133 and K1 cells when cells were treated with 40 μM SFN for 4 h Several previous studies have shown that SFN induces ROS
*toxicity∅, we did not find significant effect of SFN on body weight and liver function of mice.
MMP↓,
eff↓, Like NAC, ASC treatment significantly attenuated anti-proliferative effect of SFN in these two cell lines

1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
Synergy↑, Sulforaphane enhanced the therapeutic potential of TRAIL in PC-3 cells and sensitized TRAIL-resistant LNCaP cells.
ROS↑,
MMP↓,
Casp3↑,
Casp9↑,
DR4↑,
DR5↑,
BAX↑,
Bak↑,
BIM↑,
NOXA↑,
Bcl-2↓,
Bcl-xL↓,
Mcl-1↓,
eff↓, quenching of ROS generation with antioxidant N-acetyl-L-cysteine conferred significant protection against sulforaphane-induced ROS generation, mitochondrial membrane potential disruption, caspase-3 activation, and apoptosis.
TumCG↓,
TumCP↓,
eff↑, enhanced the antitumor activity of TRAIL.
NF-kB↓,
PI3K↓,
Akt↓,
MEK↓,
ERK↓,
angioG↓, combination of sulforaphane and TRAIL was more effective in inhibiting markers of angiogenesis and metastasis and activating FOXO3a transcription factor than single agent alone.
FOXO3↑,

963- SFN,    Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells
- in-vitro, CRC, HCT116 - in-vitro, GC, AGS
Hif1a↓,
VEGF↓,
angioG↓,
Akt∅, AKT and ERK signaling pathway is not involved in downregulation of HIF-1α protein by sulforaphane under hypoxic conditions
ERK∅,

1513- SFN,  acetaz,    Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
- in-vitro, BrCC, H720 - in-vivo, BrCC, NA - in-vitro, BrCC, H727
Synergy↑, Combining AZ+SFN reduced tumor cell survival compared to each agent alone, both in vitro and in vivo xenograft tissues.
tumCV↓,
Apoptosis↑,
P21↑,
PI3K↓,
Akt↓,
mTOR↓,
5HT↓, significantly reducing 5-HT secretion in carcinoid syndrome.
NRF2↑, AZ and SFN increased the expression of Nrf2 by 61% and 104%, respectively. Combination treatment further increased expression by 127%

1726- SFN,    Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential
- Review, Var, NA
Dose↝, Most clinical trials utilize doses of GFN ranging from 25 to 800 μmol , translating to about 65–2105 g raw broccoli or 3/4 to 23 cups of raw broccoli.
eff↝, SFN-rich powders have been made by drying out broccoli sprout
IL1β↓,
IL6↓,
IL12↓,
TNF-α↓,
COX2/PTGS2↓,
CXCR4↓,
MPO↓,
HSP70/HSPA5↓,
HSP90↓,
VCAM-1↓,
IKKα↓,
NF-kB↓,
HO-1↑,
Casp3↑,
Casp7↑,
Casp8↑,
Casp9↑,
cl‑PARP↑,
Cyt‑c↑,
Diablo↑,
CHOP/DDIT3↑,
survivin↓,
XIAP↓,
p38↑,
Fas↑,
PUMA↑,
VEGF↓,
Hif1a↓,
Twist↓,
Zeb1↓,
Vim↓,
MMP2↓,
MMP9↓,
E-cadherin↑,
N-cadherin↓,
Snail↓,
CD44↓,
cycD1/CCND1↓,
cycA1/CCNA1↓,
CycB/CCNB1↓,
cycE/CCNE↓,
CDK4↓,
CDK6↓,
p50↓,
P53↑,
P21↑,
GSH↑,
SOD↑,
GSTs↑,
mTOR↓,
Akt↓,
PI3K↓,
β-catenin/ZEB1↓,
IGF-1↓,
cMyc↓,
CSCs↓, Inhibited TS-induced, CSC-like properties

1475- SFN,  Form,    Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway
- in-vitro, Cerv, HeLa
TumCP↓,
PI3K↓,
Akt↓,
mTOR↓,
Synergy↑, cytotoxicity of FN and SFN was determined to be around 23.7 µM and 26.92 µM, respectively. Combining FN and SFN causes considerable cytotoxicity in HeLa cells, with an IC50 of 21.6 µM
ROS↑, considerable ROS generation

9188- SFN,    Broccoli-Derived Sulforaphane and Chemoprevention of Prostate Cancer: From Bench to Bedside
- Review, Pca, NA
chemoPv↑, review aims to focus specifically on SFN and its chemopreventive and antineoplastic activity against prostate cancer.
antiNeop↑,
Risk↓, Dietary intake of cruciferous vegetables is associated with a reduction in prostate cancer risk in epidemiological studies. observing a 39% reduction in prostate cancer risk between subjects with the highest and lowest quintile of cruciferous vegeta
Ingr↝, broccoli is a rich source of SFN, whereas phenethyl isothiocyanate is predominant in watercress. Other commonly studied isothiocyanates include benzyl isothiocyanate and allyl isothiocyanate.
NRF2↑, well-understood that induction of Phase 2 enzymes is mediated by the Keap1-Nrf2-antioxidant response element axis
NQO1↑, SFN produces robust and sustained transcriptional induction of NQO1 gene expression that was accompanied by similar increases in NQO1 enzymatic activity in human prostate cells in vitro [
ROS↑, treatment of prostate cancer cells with SFN generates reactive oxygen species (ROS) with disruption of mitochondrial membrane potential and cytosolic release of cytochrome c, resulting in apoptosis in PC-3 and DU145 prostate cancer cells lines
MMP↓,
Cyt‑c↑,
Apoptosis↑,
STAT3↓, we also showed SFN-induced inhibition of oncogenic transcription factor STAT3 and reduced levels of STAT3-regulated genes including bcl-2, cyclinD1 and survivin
Bcl-2↓,
cycD1/CCND1↓,
survivin↓,
HDAC↓, SFN (and its metabolites) inhibit HDAC and DNA methyltransferases (DNMT) enzymes,
DNMTs↓,
HDAC3↓, SFN lowers the expression of specific HDAC proteins including HDAC3 and HDAC6.
HDAC6↓,
Akt↓, Attenuated AKT signaling after treatment with SFN has been shown in prostate cell cultures and also in-vivo in a mouse model
TumCG↓, oral administration of broccoli sprouts to TRAMP mice showing significant retardation of prostate tumor growth at doses of 240 mg sprouts/mouse/day administered for 16 weeks
BioAv↑, single dose of 200 μmol of broccoli sprout (largely SFN), resulted in rapid absorption. ITC concentrations reached peak value of 0.943–2.27 μmol/L in plasma. Orally administered SFN has good bioavailability in various tissues (including prostate
Half-Life↝, erythrocytes at 1 h after feeding and declined with first-order kinetics (half-life of 1.77 ± 0.13 hours)
PSA↓, 200 μmol of SFN for up to 20 weeks [56]. Eighteen of the twenty patients. Seven patients had a decline in PSA with one patient having a decline by >50%.
PSADT↑, PSA doubling time improved from 6.1 months pre-study to 9.6 months on-study


Showing Research Papers: 1 to 16 of 16

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ARE↑, 1,   GSH↑, 1,   GSTs↑, 1,   HO-1↑, 2,   MPO↓, 1,   NQO1↑, 1,   NRF2↑, 5,   ROS↓, 1,   ROS↑, 9,   SOD↑, 1,   Trx↑, 1,   TrxR↓, 1,   TrxR↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↓, 1,   compIII↓, 1,   ETC↓, 1,   OCR↓, 1,   OXPHOS↓, 1,   PDH↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   ATP↓, 2,   Glycolysis↓, 1,   HK2↓, 2,   PDK1 / PDPK1↓, 1,   PKM2↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 6,   Bak↑, 1,   BAX↑, 5,   Bax:Bcl2↑, 2,   Bcl-2↓, 2,   Bcl-2∅, 1,   Bcl-xL↓, 2,   BIM↑, 2,   Casp↑, 1,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp7↑, 1,   cl‑Casp7↑, 1,   Casp8↑, 2,   Casp8∅, 1,   Casp9↑, 4,   Cyt‑c↑, 3,   Diablo↑, 1,   DR5↑, 2,   Fas↑, 1,   Mcl-1↓, 1,   NOXA↑, 1,   p38↓, 1,   p38↑, 2,   PUMA↑, 1,   survivin↓, 2,   TRAIL↑, 1,   XIAP↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 12,   Akt∅, 1,   p‑Akt↓, 3,   AKT1↓, 1,   EGFR↓, 2,   ERK↓, 1,   ERK↑, 1,   ERK∅, 1,   HER2/EBBR2↓, 2,   IKKα↓, 1,   MEK↓, 1,   mTOR↓, 6,   p‑mTOR↓, 1,   p70S6↓, 1,   PI3K↓, 9,   PTEN↑, 1,   STAT3↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

cMyc↓, 1,   DNMT1↓, 1,   DNMTs↓, 2,   FOXO1↓, 1,   FOXO3↓, 1,   FOXO3↑, 1,   HDAC↓, 4,   HDAC3↓, 2,   HDAC4↓, 1,   HDAC6↓, 1,   HDAC8↓, 1,   OCT4↓, 1,   SOX2↓, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   P53↑, 2,   p‑PARP↑, 1,   cl‑PARP↑, 3,   Telomerase↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 2,   CDK6↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   p19↑, 1,   P21↑, 6,   p27/CDKN1B↑, 2,   TumCCA?, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 3,   IGF-1↓, 1,   Nanog↓, 1,   NOTCH2↑, 1,   TumCG↓, 5,   TumCP↓, 3,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   E-cadherin↑, 2,   EMT↓, 1,   MMP2↓, 4,   MMP9↓, 3,   N-cadherin↓, 1,   Slug↓, 1,   Snail↓, 2,   TumCI↓, 1,   TumCMig↓, 2,   Twist↓, 2,   Vim↓, 1,   Zeb1↓, 2,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   CD31/PECAM-1↓, 1,   Hif1a↓, 3,   NO↑, 1,   VCAM-1↓, 1,   VEGF↓, 3,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 7,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 2,   COX2/PTGS2↓, 2,   CXCR4↓, 1,   DR4↑, 1,   IL12↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 6,   p50↓, 1,   PSA↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

SXR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   ChemoSen?, 1,   ChemoSen↑, 3,   CYP1A1↓, 1,   CYP1A2↓, 1,   CYP1B1↓, 1,   CYP3A4↓, 1,   Dose↝, 4,   eff↓, 5,   eff↑, 2,   eff↝, 1,   Half-Life↝, 1,   P450↓, 1,   RadioS↑, 1,   selectivity↝, 1,   Synergy↑, 16,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,   HER2/EBBR2↓, 2,   IL6↓, 1,   PSA↓, 1,   PSADT↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   antiNeop↑, 1,   chemoP↑, 1,   chemoPv↑, 2,   Risk↓, 3,   toxicity↓, 1,   TumW↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 1,   GutMicro↝, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 1,   Ingr↝, 1,  
Total Targets: 179

Pathway results for Effect on Normal Cells:


Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 2

Scientific Paper Hit Count for: Akt, PKB-Protein kinase B
16 Sulforaphane (mainly Broccoli)
3 Isothiocyanates
2 Benzyl isothiocyanate
1 Inulin Prebiotic
1 Allyl isothiocyanate
1 Phenethyl isothiocyanate
1 salinomycin
1 Auranofin
1 acetazolamide
1 Formononetin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:156  Target#:4  State#:%  Dir#:%
wNotes=on sortOrder:rid,rpid

 

Home Page